EMA Authorised: Siklos (hydroxycarbamide) — Theravia

View source ↗

Summary

Authorization of Siklos (hydroxycarbamide) in the European market for anemia and sickle cell indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Sickle Cell Disease

Drugs mentioned

• SIKLOS (Hydroxyurea)

Snippet

Status: Authorised. Therapeutic area: Anemia, Sickle Cell. MAH: Theravia. Decision date: 28/04/2026